Virax Biolabs Group (NASDAQ:VRAX) Stock Rating Upgraded by Wall Street Zen

Virax Biolabs Group (NASDAQ:VRAX) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Monday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Virax Biolabs Group in a report on Monday, July 6th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Virax Biolabs Group has an average rating of “Hold” and a consensus target price of $25.00.

Virax Biolabs Group Price Performance

Virax Biolabs Group stock opened at $4.08 on Monday. The company has a fifty day moving average price of $4.47 and a two-hundred day moving average price of $5.39. Virax Biolabs Group has a 12 month low of $2.50 and a 12 month high of $28.50.

Virax Biolabs Group (NASDAQ:VRAX) last released its earnings results on Friday, July 3rd. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($1.75) by $1.55. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. As a group, sell-side analysts expect that Virax Biolabs Group will post -6 EPS for the current year.

Trending Headlines about Virax Biolabs Group

Here are the key news stories impacting Virax Biolabs Group this week:

• Positive Sentiment: Virax announced an exclusive multi-country commercial supply agreement with Fosun Diagnostics covering six Southeast Asian markets. The deal gives the company an immediate path to product supply for its ImmuneSelect immune-profiling line and could create near-term revenue opportunities. Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
• Positive Sentiment: Investor enthusiasm also appears to have been boosted by media coverage describing the Fosun agreement as a breakthrough that sent the shares sharply higher and even triggered temporary trading halts due to volatility.
• Neutral Sentiment: Virax completed the closing of previously announced preferred investment option exercises, generating $3.3 million in gross proceeds and issuing new warrants. This strengthens the balance sheet, but it also adds dilution risk. Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
• Neutral Sentiment: Short-interest data showed a steep drop in short positions in late June, which suggests bearish pressure has eased, though the latest July figure appears inconsistent and may not be meaningful.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.